May 8, 2021

S2-E24.2 – From The Fourth Global NASH Congress — How Treatment WIll Evolve Over The Next Several Years

After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This conversation is organized around adoption of non-invasive testing in clinical development and when drugs will come to market.

After hearing presentations from 43 speakers at the Fourth Global NASH Congress, the Surfing the NASH Tsunami team convenes one more time to debate how long it will take before we have new medicines to use in identifying and treating patients. This is related to the question of when FDA and EMEA will accept non-invasive tests in pivotal trials. There was some disagreement on the year in which events will happen, but not on the basic pattern of market evolution.

TOPICS: 89bio, Akero Therapeutics, aldafermin, cirrhosis, efruxifermin, FDA, Fibrosis Level 3, Fibrosis Level 4, Genfit, Gilead Sciences, inventiva, lanifibranor, Madrigal, NAFLD, NASH, NGM Biopharmaceuticals, non-invasive liver testing, Semaglutide, Cyclophyllin inhibitors, CRV 431, anti-fibrotic therapy, resmetirom, FGF-19

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

S2-E24.2 – From The Fourth Global NASH Congress — How Treatment WIll Evolve Over The Next Several Years

The NASH Tsunami In Diabetes

Listen Now

S2-E24.2 – From The Fourth Global NASH Congress — How Treatment WIll Evolve Over The Next Several Years

The NASH Tsunami In Diabetes

Categories for NASH Tsunami

Listen Now